{"id":"desonide","rwe":[{"pmid":"41861782","year":"2026","title":"Hijacking ERAD for targeted degradation of transmembrane proteins.","finding":"","journal":"Cell","studyType":"Clinical Study"},{"pmid":"41730175","year":"2026","title":"Drugs for atopic dermatitis.","finding":"","journal":"The Medical letter on drugs and therapeutics","studyType":"Clinical Study"},{"pmid":"41709500","year":"2026","title":"Investigating the Telomerase Downregulatory Potential of Steroidal Drugs Following Pharmacophore-Based Rational; Computational and In Vitro Assessments.","finding":"","journal":"Archiv der Pharmazie","studyType":"Clinical Study"},{"pmid":"41607028","year":"2026","title":"Hydroxybutyl Chitosan Hydrogel Promotes Ablative Fractional CO(2) Laser Wound Healing: A Prospective, Randomized, Split-Face Trial and Animal Model Evidence.","finding":"","journal":"Lasers in surgery and medicine","studyType":"Clinical Study"},{"pmid":"41084299","year":"2026","title":"Letters: The Paradox of Desonide: Treating Inflammation, Triggering Allergy.","finding":"","journal":"Dermatitis : contact, atopic, occupational, drug","studyType":"Clinical Study"}],"_fda":{"id":"2ba564bf-266b-44d7-9d5f-40e20336b318","set_id":"0665dd04-1d0b-45bf-90e4-c6e0bd90956d","openfda":{"nui":["N0000175576","N0000175450"],"unii":["J280872D1O"],"route":["TOPICAL"],"rxcui":["349351"],"spl_id":["2ba564bf-266b-44d7-9d5f-40e20336b318"],"brand_name":["Desonide"],"spl_set_id":["0665dd04-1d0b-45bf-90e4-c6e0bd90956d"],"package_ndc":["16714-729-01","16714-729-02"],"product_ndc":["16714-729"],"generic_name":["DESONIDE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["DESONIDE"],"pharm_class_epc":["Corticosteroid [EPC]"],"pharm_class_moa":["Corticosteroid Hormone Receptor Agonists [MoA]"],"manufacturer_name":["NORTHSTAR RX LLC"],"application_number":["ANDA073548"],"is_original_packager":[true]},"version":"4","pregnancy":["Pregnancy Teratogenic Effects Corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. Some corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. Animal reproductive studies have not been conducted with desonide cream, 0.05%. It is also not known whether desonide cream, 0.05% can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. There are no adequate and well-controlled studies in pregnant women. Desonide cream, 0.05% should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus."],"overdosage":["OVERDOSAGE Topically applied desonide cream, 0.05% can be absorbed in sufficient amounts to produce systemic effects (see PRECAUTIONS )."],"description":["DESCRIPTION Desonide Cream, 0.05% contains desonide (Pregna-1,4-diene-3,20-dione,11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-,(11β,16α-)) a synthetic corticosteroid for topical dermatologic use. The corticosteroids constitute a class of primary synthetic steroids used topically as anti-inflammatory and antipruritic agents. Chemically, desonide, the active ingredient in Desonide Cream, 0.05%, is C 24 H 32 O 6 . It has the following structural formula: The molecular weight of desonide is 416.51. It is a white to off-white odorless powder which is soluble in methanol and practically insoluble in water. Each gram of Desonide Cream, 0.05% contains 0.5 milligram of desonide in a compatible vehicle buffered to the pH range of normal skin. It contains aluminum acetate basic, cetearyl alcohol/sodium lauryl sulfate/sodium cetearyl sulfate, glycerin, mineral oil, purified water, white petrolatum and white wax. It is preserved with methylparaben. Chemical Structure"],"precautions":["PRECAUTIONS General Systemic absorption of topical corticosteroids can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for glucocorticosteroid insufficiency after withdrawal of treatment. Manifestations of Cushing's syndrome, hyperglycemia, and glucosuria can also be produced in some patients by systemic absorption of topical corticosteroids while on treatment. Patients applying a topical steroid to a large surface area or to areas under occlusion should be evaluated periodically for evidence of HPA axis suppression. This may be done by using the ACTH stimulation, A.M. plasma cortisol, and urinary free cortisol tests. Patients receiving superpotent corticosteroids should not be treated for more than two weeks at a time and only small areas should be treated at any one time due to the increased risk of HPA suppressions. One of ten patients treated for one week under occlusion (30% of body surface) with desonide cream, 0.05% developed HPA axis suppression as determined by metapyrone testing. If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent corticosteroid. Recovery of HPA axis function is generally prompt upon discontinuation of topical corticosteroids. Infrequently, signs and symptoms of glucocorticosteroid insufficiency may occur requiring supplemental systemic corticosteroids. For information on systemic supplementation, see prescribing information for those products. Pediatric patients may be more susceptible to systemic toxicity from equivalent doses due to their larger skin surface to body mass ratios (See PRECAUTIONS - Pediatric Use ). If irritation develops, desonide cream, 0.05% should be discontinued and appropriate therapy instituted. Allergic contact dermatitis with corticosteroids is usually diagnosed by observing a failure to heal rather than noting a clinical exacerbation as with most topical products not containing corticosteroids. Such an observation should be corroborated with appropriate diagnostic patch testing. If concomitant skin infections are present or develop, an appropriate antifungal or antibacterial agent should be used. If a favorable response does not occur promptly, use of desonide cream, 0.05% should be discontinued until the infection has been adequately controlled. Desonide cream, 0.05% should not be used in the presence of infection at the treatment site, hypersensitivity to corticosteroids, or pre-existing skin atrophy. Desonide cream, 0.05% should not be used in the eyes. FOR EXTERNAL USE ONLY. Information for Patients Patients using topical corticosteroids should receive the following information and instructions: This medication is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes. This medication should not be used for any disorder other than that for which it was prescribed. The treated skin area should not be bandaged, or otherwise covered or wrapped, so as to be occlusive unless directed by the physician. Patients should report to their physician any signs of local adverse reactions. Laboratory Tests The following tests may be helpful in evaluating patients for HPA axis suppression: ACTH stimulation test A.M. plasma cortisol test Urinary free cortisol test Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term animal studies have not been performed to evaluate the carcinogenic, mutagenic, or fertility impairment potential of desonide cream, 0.05%. Pregnancy Teratogenic Effects Corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. Some corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. Animal reproductive studies have not been conducted with desonide cream, 0.05%. It is also not known whether desonide cream, 0.05% can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. There are no adequate and well-controlled studies in pregnant women. Desonide cream, 0.05% should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Nursing Mothers Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk. Because many drugs are excreted in human milk, caution should be exercised when desonide cream, 0.05% is administered to a nursing woman. Pediatric Use Safety and effectiveness in pediatric patients have not been established. Because of a higher ratio of skin surface area to body mass, pediatric patients are at a greater risk than adults of HPA axis suppression and Cushing's syndrome when they are treated with topical corticosteroids. They are therefore also at greater risk of adrenal insufficiency during or after withdrawal of treatment. Adverse effects including striae have been reported with inappropriate use of topical corticosteroids in infants and children. HPA axis suppression, Cushing's syndrome, linear growth retardation, delayed weight gain and intracranial hypertension have been reported in children receiving topical corticosteroids. Manifestations of adrenal suppression in children include low plasma cortisol levels and absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema."],"how_supplied":["HOW SUPPLIED Desonide Cream, 0.05% is supplied in 15 g (NDC 16714-729-01) tubes. Desonide Cream, 0.05% is supplied in 60 g (NDC 16714-729-02) tubes. STORAGE Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Protect from freezing."],"pediatric_use":["Pediatric Use Safety and effectiveness in pediatric patients have not been established. Because of a higher ratio of skin surface area to body mass, pediatric patients are at a greater risk than adults of HPA axis suppression and Cushing's syndrome when they are treated with topical corticosteroids. They are therefore also at greater risk of adrenal insufficiency during or after withdrawal of treatment. Adverse effects including striae have been reported with inappropriate use of topical corticosteroids in infants and children. HPA axis suppression, Cushing's syndrome, linear growth retardation, delayed weight gain and intracranial hypertension have been reported in children receiving topical corticosteroids. Manifestations of adrenal suppression in children include low plasma cortisol levels and absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema."],"effective_time":"20230719","nursing_mothers":["Nursing Mothers Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk. Because many drugs are excreted in human milk, caution should be exercised when desonide cream, 0.05% is administered to a nursing woman."],"laboratory_tests":["Laboratory Tests The following tests may be helpful in evaluating patients for HPA axis suppression: ACTH stimulation test A.M. plasma cortisol test Urinary free cortisol test"],"pharmacokinetics":["Pharmacokinetics The extent of percutaneous absorption of topical corticosteroids is determined by many factors, including the vehicle and the integrity of the epidermal barrier. Occlusive dressings with hydrocortisone for up to 24 hours have not been demonstrated to increase penetration; however, occlusion of hydrocortisone for 96 hours markedly enhances penetration. Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin may increase percutaneous absorption. Studies performed with desonide cream, 0.05% indicate that it is in the low range of potency as compared with other topical corticosteroids."],"adverse_reactions":["ADVERSE REACTIONS In controlled clinical trials, the total incidence of adverse reactions associated with the use of desonide cream, 0.05% was approximately 1%. The adverse reactions for desonide cream, 0.05% were pruritus, pain, folliculitis, rash, peripheral edema, pustular rash, sweating, erythema, irritation, and burning. Laboratory abnormalities were found in 3% of the patients. These were hyperglycemia (2%) and liver function abnormality (1%). The following additional local adverse reactions have been reported infrequently with topical corticosteroids, and they may occur more frequently with the use of occlusive dressings and higher potency corticosteroids. These reactions are listed in approximate decreasing order of occurrence: dryness, folliculitis, acneiform eruptions, perioral dermatitis, allergic contact dermatitis, secondary infection, skin atrophy, striae, miliaria, burning and hypopigmentation."],"contraindications":["CONTRAINDICATIONS Desonide cream, 0.05% is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation."],"general_precautions":["General Systemic absorption of topical corticosteroids can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for glucocorticosteroid insufficiency after withdrawal of treatment. Manifestations of Cushing's syndrome, hyperglycemia, and glucosuria can also be produced in some patients by systemic absorption of topical corticosteroids while on treatment. Patients applying a topical steroid to a large surface area or to areas under occlusion should be evaluated periodically for evidence of HPA axis suppression. This may be done by using the ACTH stimulation, A.M. plasma cortisol, and urinary free cortisol tests. Patients receiving superpotent corticosteroids should not be treated for more than two weeks at a time and only small areas should be treated at any one time due to the increased risk of HPA suppressions. One of ten patients treated for one week under occlusion (30% of body surface) with desonide cream, 0.05% developed HPA axis suppression as determined by metapyrone testing. If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent corticosteroid. Recovery of HPA axis function is generally prompt upon discontinuation of topical corticosteroids. Infrequently, signs and symptoms of glucocorticosteroid insufficiency may occur requiring supplemental systemic corticosteroids. For information on systemic supplementation, see prescribing information for those products. Pediatric patients may be more susceptible to systemic toxicity from equivalent doses due to their larger skin surface to body mass ratios (See PRECAUTIONS - Pediatric Use ). If irritation develops, desonide cream, 0.05% should be discontinued and appropriate therapy instituted. Allergic contact dermatitis with corticosteroids is usually diagnosed by observing a failure to heal rather than noting a clinical exacerbation as with most topical products not containing corticosteroids. Such an observation should be corroborated with appropriate diagnostic patch testing. If concomitant skin infections are present or develop, an appropriate antifungal or antibacterial agent should be used. If a favorable response does not occur promptly, use of desonide cream, 0.05% should be discontinued until the infection has been adequately controlled. Desonide cream, 0.05% should not be used in the presence of infection at the treatment site, hypersensitivity to corticosteroids, or pre-existing skin atrophy. Desonide cream, 0.05% should not be used in the eyes. FOR EXTERNAL USE ONLY."],"teratogenic_effects":["Teratogenic Effects Corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. Some corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. Animal reproductive studies have not been conducted with desonide cream, 0.05%. It is also not known whether desonide cream, 0.05% can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. There are no adequate and well-controlled studies in pregnant women. Desonide cream, 0.05% should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus."],"storage_and_handling":["STORAGE Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Protect from freezing."],"clinical_pharmacology":["CLINICAL PHARMACOLOGY Like other topical corticosteroids, desonide has anti-inflammatory, antipruritic and vasoconstrictive properties. The mechanism of the anti-inflammatory activity of the topical steroids, in general, is unclear. However corticosteroids are thought to act by the induction of phospholipase A 2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A 2 . Pharmacokinetics The extent of percutaneous absorption of topical corticosteroids is determined by many factors, including the vehicle and the integrity of the epidermal barrier. Occlusive dressings with hydrocortisone for up to 24 hours have not been demonstrated to increase penetration; however, occlusion of hydrocortisone for 96 hours markedly enhances penetration. Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin may increase percutaneous absorption. Studies performed with desonide cream, 0.05% indicate that it is in the low range of potency as compared with other topical corticosteroids."],"indications_and_usage":["INDICATIONS AND USAGE Desonide cream, 0.05% is a low potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. It should not be used for longer than two weeks unless directed by a physician."],"information_for_patients":["Information for Patients Patients using topical corticosteroids should receive the following information and instructions: This medication is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes. This medication should not be used for any disorder other than that for which it was prescribed. The treated skin area should not be bandaged, or otherwise covered or wrapped, so as to be occlusive unless directed by the physician. Patients should report to their physician any signs of local adverse reactions."],"spl_unclassified_section":["For Dermatologic Use Only Not For Ophthalmic Use Rx Only","Manufactured for: Northstar RxLLC, Memphis, TN 38141 Manufactured by: Taro Pharmaceutical Industries Ltd. Toll Free: 1-800-206-7821 Haifa Bay, Israel 2624761 Product of Italy Revised: June 2020 21092-0620-2 52"],"dosage_and_administration":["DOSAGE AND ADMINISTRATION Desonide cream, 0.05% should be applied to the affected area as a thin film two to four times daily depending on the severity of the condition. As with other corticosteroids, therapy should be discontinued when control is achieved. If no improvement is seen within two weeks, reassessment of diagnosis may be necessary. Desonide cream, 0.05% should not be used with occlusive dressings."],"spl_product_data_elements":["Desonide Desonide Desonide Desonide ALUMINUM SUBACETATE CETOSTEARYL ALCOHOL SODIUM LAURYL SULFATE SODIUM CETOSTEARYL SULFATE glycerin methylparaben mineral oil water PETROLATUM white wax"],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL - 60 g Tube Carton Rx only NDC 16714-729-02 Desonide Cream 0.05% FOR EXTERNAL USE ONLY. NOT FOR OPHTHALMIC USE. NORTHSTARX ® 60 g PRINCIPAL DISPLAY PANEL - 60 g Tube Carton"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term animal studies have not been performed to evaluate the carcinogenic, mutagenic, or fertility impairment potential of desonide cream, 0.05%."]},"tags":[{"label":"Corticosteroid","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Glucocorticoid receptor","category":"target"},{"label":"NR3C1","category":"gene"},{"label":"D07AB08","category":"atc"},{"label":"Topical","category":"route"},{"label":"Aerosol","category":"form"},{"label":"Cream","category":"form"},{"label":"Gel","category":"form"},{"label":"Lotion","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Established","category":"status"},{"label":"Allergic Rhinitis Prevention","category":"indication"},{"label":"Allergic rhinitis","category":"indication"},{"label":"Asthma","category":"indication"},{"label":"Asthma management","category":"indication"},{"label":"Atopic dermatitis","category":"indication"},{"label":"Chronic Non-Allergic Rhinitis","category":"indication"},{"label":"Padagis Us","category":"company"},{"label":"Approved 1970s","category":"decade"},{"label":"Anti-Inflammatory Agents","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"1136 reports"},{"date":"","signal":"MACULAR DEGENERATION","source":"FDA FAERS","actionTaken":"773 reports"},{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"397 reports"},{"date":"","signal":"PAIN","source":"FDA FAERS","actionTaken":"377 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"365 reports"},{"date":"","signal":"HEADACHE","source":"FDA FAERS","actionTaken":"315 reports"},{"date":"","signal":"ERYTHEMA","source":"FDA FAERS","actionTaken":"301 reports"},{"date":"","signal":"PYREXIA","source":"FDA FAERS","actionTaken":"299 reports"},{"date":"","signal":"RASH","source":"FDA FAERS","actionTaken":"297 reports"},{"date":"","signal":"PRURITUS","source":"FDA FAERS","actionTaken":"295 reports"}],"commonSideEffects":[{"effect":"hyperglycemia","drugRate":"2%","_validated":true,"placeboRate":""},{"effect":"liver function abnormality","drugRate":"1%","_validated":true,"placeboRate":""}],"contraindications":["Desonide cream, 0.05% is contraindicated in patients with a history of hypersensitivity to any of the components of the preparation."],"specialPopulations":{"Pregnancy":"Corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. Some corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. Therefore, Desonide Gel, 0.05% should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.","Geriatric use":"Clinical trials of VERDESO Foam did not include any subjects aged 65 or over to determine whether they respond differently from younger subjects. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.","Paediatric use":"Safety and effectiveness in pediatric patients have not been established. Because of higher ratio of skin surface area to body mass, pediatric patients are at greater risk than adults of HPA axis suppression when they are treated with topical corticosteroids. They are therefore also at greater risk of glucocorticosteroid insufficiency after withdrawal of treatment and of Cushing's syndrome while on treatment."}},"trials":[],"aliases":[],"company":"Padagis Us","patents":[{"type":"Formulation","number":"8460641","applicant":"ALMIRALL LLC","territory":"US","tradeName":"VERDESO","expiryDate":"2027-08-13"}],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$0.3723/GM","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$136","description":"DESONIDE 0.05% CREAM","retrievedDate":"2026-04-07"}],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=DESONIDE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:49:36.898977+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T00:49:36.898738+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:49:43.400891+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T00:49:35.535483+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=DESONIDE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:49:44.227542+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:49:33.647896+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:49:33.647931+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:49:33.647937+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T00:49:45.758812+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Glucocorticoid receptor agonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:49:44.825286+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201109/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:49:44.703184+00:00"},"safety.commonSideEffects":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"ADVERSE REACTIONS In controlled clinical trials, the total incidence of adverse reactions associated with the use of desonide cream, 0.05% was approximately 1%. The adverse reactions for desonide cream, 0.05% were pruritus, pain, folliculitis, rash, peripheral edema, pustular rash, sweating, erythema, irritation, and burning. Laboratory abnormalities were found in 3% of the patients. These were hyperglycemia (2%) and liver function abnormality (1%). The following additional local adverse reactio","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:49:51.456613+00:00"},"safety.contraindications":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:49:54.649990+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA073548","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:49:33.647941+00:00"}},"allNames":"verdeso","offLabel":[],"synonyms":["desonide","budesonide acetonide","prednacinolone"],"timeline":[{"date":"1972-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from PERRIGO NEW YORK to Padagis Us"},{"date":"1984-12-14","type":"positive","source":"FDA Orange Book","milestone":"Desowen approved — 0.05%"},{"date":"2006-09-19","type":"positive","source":"FDA Orange Book","milestone":"Verdeso approved — 0.05%"},{"date":"2006-10-20","type":"positive","source":"FDA Orange Book","milestone":"Desonate approved — 0.05% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**"},{"date":"2020-08-24","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 13 manufacturers approved"}],"aiSummary":"Verdeso (Desonide) is a corticosteroid medication that targets the glucocorticoid receptor to treat various inflammatory conditions. Originally developed by PERRIGO NEW YORK, it is now owned by Padagis Us. Verdeso is a small molecule modality that has been FDA-approved since 1972 for multiple indications, including allergic rhinitis, asthma, and atopic dermatitis. The medication is available as a generic product with 13 manufacturers, making it an off-patent drug. As an off-patent corticosteroid, Verdeso's commercial status is generic, with no active Orange Book patents.","approvals":[{"date":"1972-01-04","orphan":false,"company":"PERRIGO NEW YORK","regulator":"FDA"}],"brandName":"Verdeso","ecosystem":[{"indication":"Allergic Rhinitis Prevention","otherDrugs":[{"name":"budesonide","slug":"budesonide","company":""},{"name":"flunisolide","slug":"flunisolide","company":""},{"name":"mometasone furoate","slug":"mometasone-furoate","company":"Merck Sharp Dohme"},{"name":"triamcinolone","slug":"triamcinolone","company":""}],"globalPrevalence":null},{"indication":"Allergic rhinitis","otherDrugs":[{"name":"acrivastine","slug":"acrivastine","company":"Auxilium Pharms Inc"},{"name":"alimemazine","slug":"alimemazine","company":"Allergan Herbert"},{"name":"antazoline","slug":"antazoline","company":"Novartis"},{"name":"astemizole","slug":"astemizole","company":""}],"globalPrevalence":null},{"indication":"Asthma","otherDrugs":[{"name":"beclometasone dipropionate","slug":"beclometasone-dipropionate","company":""},{"name":"betamethasone","slug":"betamethasone","company":""},{"name":"betamethasone acetate","slug":"betamethasone-acetate","company":""},{"name":"bitolterol","slug":"bitolterol","company":"Sanofi Aventis Us"}],"globalPrevalence":262000000},{"indication":"Asthma management","otherDrugs":[{"name":"beclometasone dipropionate","slug":"beclometasone-dipropionate","company":""},{"name":"bitolterol","slug":"bitolterol","company":"Sanofi Aventis Us"},{"name":"budesonide","slug":"budesonide","company":""},{"name":"ciclesonide","slug":"ciclesonide","company":"Takeda Gmbh"}],"globalPrevalence":262000000},{"indication":"Atopic dermatitis","otherDrugs":[{"name":"abrocitinib","slug":"abrocitinib","company":"PFIZER Inc"},{"name":"alclometasone dipropionate","slug":"alclometasone-dipropionate","company":""},{"name":"amcinonide","slug":"amcinonide","company":"Astellas"},{"name":"ammonium lactate","slug":"ammonium-lactate","company":"Ranbaxy"}],"globalPrevalence":204050000},{"indication":"Chronic Non-Allergic Rhinitis","otherDrugs":[{"name":"budesonide","slug":"budesonide","company":""},{"name":"flunisolide","slug":"flunisolide","company":""},{"name":"fluticasone furoate","slug":"fluticasone-furoate","company":"Glaxosmithkline"},{"name":"fluticasone propionate","slug":"fluticasone-propionate","company":"Fougera Pharms"}],"globalPrevalence":null},{"indication":"Contact dermatitis","otherDrugs":[{"name":"alclometasone dipropionate","slug":"alclometasone-dipropionate","company":""},{"name":"amcinonide","slug":"amcinonide","company":"Astellas"},{"name":"ammonium lactate","slug":"ammonium-lactate","company":"Ranbaxy"},{"name":"benzoyl peroxide","slug":"benzoyl-peroxide","company":"Valeant Intl"}],"globalPrevalence":324000000},{"indication":"Crohn's disease","otherDrugs":[{"name":"adalimumab","slug":"adalimumab","company":"Abbvie Inc"},{"name":"azathioprine","slug":"azathioprine","company":"Prometheus Labs"},{"name":"betamethasone","slug":"betamethasone","company":""},{"name":"betamethasone acetate","slug":"betamethasone-acetate","company":""}],"globalPrevalence":5000000}],"mechanism":{"target":"Glucocorticoid receptor","novelty":"Follow-on","targets":[{"gene":"NR3C1","source":"DrugCentral","target":"Glucocorticoid receptor","protein":"Glucocorticoid receptor"}],"moaClass":"Corticosteroid Hormone Receptor Agonists","modality":"Small Molecule","drugClass":"Corticosteroid [EPC]","explanation":"","oneSentence":"","technicalDetail":"Verdeso (Desonide) is a synthetic corticosteroid that selectively binds to the glucocorticoid receptor (GR), a transcription factor that regulates the expression of genes involved in inflammation and immune responses. By activating GR, Verdeso inhibits the transcription of pro-inflammatory genes and promotes the expression of anti-inflammatory genes, leading to a reduction in inflammation and immune responses."},"commercial":{"launchDate":"1972","revenueYear":2024,"_launchSource":"DrugCentral (FDA 1972-01-04, PERRIGO NEW YORK)","annualRevenue":2800,"revenueSource":"Verified: AstraZeneca AR","revenueCurrency":"USD","revenueConfidence":"verified"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3135","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=DESONIDE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=DESONIDE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T10:29:27.951009","_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T00:49:55.859258+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"hydrocortisone butyrate","drugSlug":"hydrocortisone-butyrate","fdaApproval":"1982-03-31","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"flumetasone","drugSlug":"flumetasone","fdaApproval":"","relationship":"same-class"},{"drugName":"fluorometholone","drugSlug":"fluorometholone","fdaApproval":"1972-01-12","genericCount":3,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"triamcinolone","drugSlug":"triamcinolone","fdaApproval":"1957-12-03","genericCount":9,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"alclometasone dipropionate","drugSlug":"alclometasone-dipropionate","fdaApproval":"1982-12-14","genericCount":3,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"hydrocortisone probutate","drugSlug":"hydrocortisone-probutate","fdaApproval":"1997-02-28","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"dexamethasone","drugSlug":"dexamethasone","fdaApproval":"1958-10-30","patentExpiry":"Oct 7, 2036","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"clocortolone pivalate","drugSlug":"clocortolone-pivalate","fdaApproval":"1977-08-22","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"genericName":"desonide","indications":{"approved":[{"name":"Allergic Rhinitis Prevention","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":null},{"name":"Allergic rhinitis","source":"DrugCentral","snomedId":61582004,"regulator":"FDA","eligibility":null},{"name":"Asthma","source":"DrugCentral","snomedId":195967001,"regulator":"FDA","eligibility":null,"usPrevalence":25000000,"globalPrevalence":262000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2023"},{"name":"Asthma management","source":"DrugCentral","snomedId":406162001,"regulator":"FDA","eligibility":null,"usPrevalence":25000000,"globalPrevalence":262000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2023"},{"name":"Atopic dermatitis","source":"DrugCentral","snomedId":24079001,"regulator":"FDA","eligibility":null,"usPrevalence":null,"globalPrevalence":204050000,"prevalenceMethod":"curated","prevalenceSource":"Br J Dermatol, 2023 (PMID:37705227)"},{"name":"Chronic Non-Allergic Rhinitis","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":null},{"name":"Contact dermatitis","source":"DrugCentral","snomedId":40275004,"regulator":"FDA","eligibility":null,"usPrevalence":null,"globalPrevalence":324000000,"prevalenceMethod":"curated","prevalenceSource":"Contact Dermatitis, 2025 (PMID:40107276)"},{"name":"Crohn's disease","source":"DrugCentral","snomedId":34000006,"regulator":"FDA","eligibility":null,"usPrevalence":780000,"globalPrevalence":5000000,"prevalenceMethod":"curated","prevalenceSource":"Lancet Gastroenterology, 2023"},{"name":"Crohn's disease in remission","source":"DrugCentral","snomedId":426549001,"regulator":"FDA","eligibility":null,"usPrevalence":780000,"globalPrevalence":5000000,"prevalenceMethod":"curated","prevalenceSource":"Lancet Gastroenterology, 2023"},{"name":"Discoid lupus erythematosus","source":"DrugCentral","snomedId":200938002,"regulator":"FDA","eligibility":null,"usPrevalence":null,"globalPrevalence":2400000,"prevalenceMethod":"curated","prevalenceSource":"Orphanet (ORPHANET)"},{"name":"Eruption of skin","source":"DrugCentral","snomedId":271807003,"regulator":"FDA"},{"name":"Granuloma annulare","source":"DrugCentral","snomedId":65508009,"regulator":"FDA"},{"name":"Lichen simplex chronicus","source":"DrugCentral","snomedId":53891004,"regulator":"FDA"},{"name":"Otitis externa","source":"DrugCentral","snomedId":3135009,"regulator":"FDA"},{"name":"Plaque psoriasis","source":"DrugCentral","snomedId":200965009,"regulator":"FDA","usPrevalence":7500000,"globalPrevalence":125000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2023"},{"name":"Primary cutaneous T-cell lymphoma","source":"DrugCentral","snomedId":400122007,"regulator":"FDA"},{"name":"Pruritus ani","source":"DrugCentral","snomedId":90446007,"regulator":"FDA"},{"name":"Pruritus of genital organs","source":"DrugCentral","snomedId":267802000,"regulator":"FDA"},{"name":"Scalp psoriasis","source":"DrugCentral","snomedId":238608008,"regulator":"FDA","usPrevalence":7500000,"globalPrevalence":125000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2023"},{"name":"Seborrheic dermatitis","source":"DrugCentral","snomedId":50563003,"regulator":"FDA"}],"offLabel":[{"name":"Otitis Externa Eczema","source":"DrugCentral","drugName":"DESONIDE","evidenceCount":0,"evidenceLevel":"emerging"},{"name":"Otitis Externa Seborrhea","source":"DrugCentral","drugName":"DESONIDE","evidenceCount":0,"evidenceLevel":"emerging"},{"name":"Severe chronic obstructive pulmonary disease","source":"DrugCentral","drugName":"DESONIDE","evidenceCount":0,"evidenceLevel":"emerging"}],"pipeline":[]},"currentOwner":"Padagis Us","drugCategory":"established","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"hydrocortisone-butyrate","brandName":"hydrocortisone butyrate","genericName":"hydrocortisone butyrate","approvalYear":"1982","relationship":"same-class"},{"drugId":"flumetasone","brandName":"flumetasone","genericName":"flumetasone","approvalYear":"","relationship":"same-class"},{"drugId":"fluorometholone","brandName":"fluorometholone","genericName":"fluorometholone","approvalYear":"1972","relationship":"same-class"},{"drugId":"triamcinolone","brandName":"triamcinolone","genericName":"triamcinolone","approvalYear":"1957","relationship":"same-class"},{"drugId":"alclometasone-dipropionate","brandName":"alclometasone dipropionate","genericName":"alclometasone dipropionate","approvalYear":"1982","relationship":"same-class"},{"drugId":"hydrocortisone-probutate","brandName":"hydrocortisone probutate","genericName":"hydrocortisone probutate","approvalYear":"1997","relationship":"same-class"},{"drugId":"dexamethasone","brandName":"dexamethasone","genericName":"dexamethasone","approvalYear":"1958","relationship":"same-class"},{"drugId":"clocortolone-pivalate","brandName":"clocortolone pivalate","genericName":"clocortolone pivalate","approvalYear":"1977","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT03437005","phase":"PHASE1","title":"Alternation in the Human Microbiome With Commonly Used Topical Medications","status":"RECRUITING","sponsor":"University of California, Davis","startDate":"2013-01-28","conditions":["Healthy"],"enrollment":24,"completionDate":"2026-09-28"},{"nctId":"NCT07295678","phase":"NA","title":"URGO FilmoCream Eczema + Dermocorticoids in Atopic Dermatitis","status":"NOT_YET_RECRUITING","sponsor":"CEN Biotech","startDate":"2026-01-05","conditions":["Atopic Dermatitis"],"enrollment":44,"completionDate":"2026-12-31"},{"nctId":"NCT02624544","phase":"PHASE4","title":"Proton Pump Inhibitors Use in Patients With Psoriasis","status":"WITHDRAWN","sponsor":"EMS","startDate":"2016-01","conditions":["Psoriasis"],"enrollment":0,"completionDate":"2016-12"},{"nctId":"NCT03386032","phase":"PHASE3","title":"8-Week Atopic Dermatitis (AD) Treatment Study","status":"COMPLETED","sponsor":"Procter and Gamble","startDate":"2017-11-27","conditions":["Atopic Dermatitis Eczema"],"enrollment":65,"completionDate":"2018-08-18"},{"nctId":"NCT03758365","phase":"PHASE1","title":"Evaluation of the Vasoconstriction Properties of MC2-01 Cream","status":"COMPLETED","sponsor":"MC2 Therapeutics","startDate":"2018-11-05","conditions":["Vasoconstriction"],"enrollment":36,"completionDate":"2018-11-23"},{"nctId":"NCT00690833","phase":"PHASE4","title":"Efficacy of Desonide (Desonatetm) Gel 0.05% in Younger and Older Subjects With Atopic Dermatitis","status":"COMPLETED","sponsor":"Wake Forest University","startDate":"2007-08","conditions":["Atopic Dermatitis"],"enrollment":41,"completionDate":"2009-11"},{"nctId":"NCT00828412","phase":"PHASE4","title":"Comparison of the Efficacy and Safety of Two Topical Creams for Pediatric Atopic Dermatitis","status":"COMPLETED","sponsor":"Promius Pharma, LLC","startDate":"2009-03","conditions":["Atopic Dermatitis"],"enrollment":100,"completionDate":"2009-08"},{"nctId":"NCT02732314","phase":"PHASE4","title":"Efficacy and Tolerability of New Topical Formulations in Subjects With Atopic Dermatitis","status":"COMPLETED","sponsor":"Procter & Gamble Beauty","startDate":"2016-03","conditions":["Dermatitis, Atopic","Eczema"],"enrollment":53,"completionDate":"2016-06"},{"nctId":"NCT02286700","phase":"PHASE3","title":"Skin Effects of a Topical Amino Acid Moisturizing Cream and Desonide in Atopic Dermatitis","status":"UNKNOWN","sponsor":"NeoStrata Company, Inc.","startDate":"2014-11","conditions":["Dermatitis, Atopic","Eczema"],"enrollment":42,"completionDate":"2015-03"},{"nctId":"NCT01779258","phase":"PHASE3","title":"Emollients in the Management of Atopic Dermatitis","status":"COMPLETED","sponsor":"Pierre Fabre Medicament","startDate":"2013-02","conditions":["Atopic Dermatitis"],"enrollment":347,"completionDate":"2014-02"},{"nctId":"NCT01935310","phase":"NA","title":"Photoaging Treatment With Imiquimod","status":"COMPLETED","sponsor":"CES University","startDate":"2010-07","conditions":["Photoaging"],"enrollment":17,"completionDate":"2013-08"},{"nctId":"NCT01467362","phase":"PHASE3","title":"Efficacy Emollient on Xerosis in Children With Atopic Dermatitis","status":"COMPLETED","sponsor":"Pierre Fabre Medicament","startDate":"2011-11","conditions":["Atopic Dermatitis"],"enrollment":251,"completionDate":"2012-05"},{"nctId":"NCT01542138","phase":"PHASE4","title":"Clinical Trial of 4% Niacinamide Versus 0.05% Desonide for the Treatment of Axillar Hyperpigmentation","status":"COMPLETED","sponsor":"Universidad Autonoma de San Luis Potosí","startDate":"2011-07","conditions":["Hyperpigmentation"],"enrollment":28,"completionDate":"2012-11"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Topical","formulation":"Aerosol, Cream, Gel, Lotion","formulations":[{"form":"AEROSOL, FOAM","route":"TOPICAL","productName":"Verdeso"},{"form":"CREAM","route":"TOPICAL","productName":"DESONIDE"},{"form":"CREAM","route":"TOPICAL","productName":"Desonide"},{"form":"CREAM","route":"TOPICAL","productName":"DesOwen"},{"form":"CREAM","route":"TOPICAL","productName":"Desonide"},{"form":"CREAM","route":"TOPICAL","productName":"Tridesilon Cream"},{"form":"CREAM","route":"TOPICAL","productName":"Desonide"},{"form":"GEL","route":"TOPICAL","productName":"DESONIDE"},{"form":"GEL","route":"TOPICAL","productName":"DESRX"},{"form":"GEL","route":"TOPICAL","productName":"DESONATE"},{"form":"LOTION","route":"TOPICAL","productName":"DesOwen"},{"form":"LOTION","route":"TOPICAL","productName":"Desonide"},{"form":"LOTION","route":"TOPICAL","productName":"LoKara"},{"form":"LOTION","route":"TOPICAL","productName":"desonide"},{"form":"OINTMENT","route":"TOPICAL","productName":"Desonide"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000146597","MMSL":"1093","NDDF":"002199","UNII":"J280872D1O","VUID":"4018267","CHEBI":"CHEBI:204734","VANDF":"4018267","INN_ID":"2889","RXNORM":"3254","UMLSCUI":"C0011705","chemblId":"CHEMBL1201109","ChEMBL_ID":"CHEMBL1201109","KEGG_DRUG":"D03696","DRUGBANK_ID":"DB01260","PUBCHEM_CID":"5311066","SNOMEDCT_US":"412363005","IUPHAR_LIGAND_ID":"7066","MESH_DESCRIPTOR_UI":"D003898"},"formularyStatus":[],"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"1972-","companyName":"Perrigo New York","relationship":"Original Developer"},{"period":"present","companyName":"Padagis Us","relationship":"Current Owner"}],"publicationCount":130,"therapeuticAreas":["Oncology"],"_revenueScrapedAt":"2026-04-08 13:57:44.251783+00","atcClassification":{"source":"DrugCentral","atcCode":"D07AB08","allCodes":["D07AB08","D07BB02","S01BA11"]},"biosimilarFilings":[],"originalDeveloper":"Perrigo New York","recentPublications":[{"date":"2026 Mar 19","pmid":"41861782","title":"Hijacking ERAD for targeted degradation of transmembrane proteins.","journal":"Cell"},{"date":"2026 Mar 2","pmid":"41730175","title":"Drugs for atopic dermatitis.","journal":"The Medical letter on drugs and therapeutics"},{"date":"2026 Feb","pmid":"41709500","title":"Investigating the Telomerase Downregulatory Potential of Steroidal Drugs Following Pharmacophore-Based Rational; Computational and In Vitro Assessments.","journal":"Archiv der Pharmazie"},{"date":"2026 Mar","pmid":"41607028","title":"Hydroxybutyl Chitosan Hydrogel Promotes Ablative Fractional CO(2) Laser Wound Healing: A Prospective, Randomized, Split-Face Trial and Animal Model Evidence.","journal":"Lasers in surgery and medicine"},{"date":"2026 Feb 25","pmid":"41084299","title":"Letters: The Paradox of Desonide: Treating Inflammation, Triggering Allergy.","journal":"Dermatitis : contact, atopic, occupational, drug"}],"companionDiagnostics":[],"genericManufacturers":13,"_genericFilersChecked":true,"genericManufacturerList":["Alembic","Cadila","Cosette","Encube Ethicals","Fougera Pharms","Galderma Labs Lp","Glenmark Pharms Ltd","Glenmark Speclt","Hikma","Pai Holdings Pharm","Senores Pharms","Sun Pharma Canada","Taro"],"status":"approved","companyName":"Padagis Us","companyId":"padagis-us","modality":"Small molecule","firstApprovalDate":"1972","enrichmentLevel":3,"visitCount":2,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1972-01-04T00:00:00.000Z","mah":"PERRIGO NEW YORK","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1980-05-01T00:00:00.000Z","mah":"PADAGIS US","brand_name_local":null,"application_number":"NDA017010"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1985-06-26T00:00:00.000Z","mah":"GALDERMA LABS LP","brand_name_local":null,"application_number":"NDA019048"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1993-05-19T00:00:00.000Z","mah":"GALDERMA LABS LP","brand_name_local":null,"application_number":"ANDA072354"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2016-01-15T00:00:00.000Z","mah":"SUN PHARMA CANADA","brand_name_local":null,"application_number":"ANDA074254"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2019-11-20T00:00:00.000Z","mah":"CADILA","brand_name_local":null,"application_number":"ANDA210198"},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"patentsNormalised":[{"patent_number":"8460641","territory":"US","patent_type":"Formulation","expiry_date":"2027-08-13T00:00:00.000Z","status":"active","paragraph_iv_filed":false}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T00:49:55.859258+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}